Scholar Rock continues to build case for entrant into SMA space

25 October 2022
scholar_big

The market for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatal, has attracted many of biopharma’s biggest names.

Biogen’s (Nasdaq: BIIB) Spinraza (nusinersen), Roche’s (ROG: SIX) Evrysdi (risdiplam) and Novartis’ (NOVN: VX) Zolgensma (onasemnogene abeparvovec) are already competing in a market predicted to be worth nearly $2.1 billion by 2026, according to Stratview Research.

But it is not just big pharma players seeking to gain a share of the growing market, with Boston, USA-based biotech Scholar Rock (Nasdaq: SRRK) hopeful of advancing apitegromab, a selective inhibitor of the activation of myostatin which is now being studied in a Phase III study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology